Amatsigroup buys French Pyrofree manufacturing specialist Disposable-Lab
According to Amatsigroup the acquisition has expanded its capabilities in injectable drug production, citing D-Lab’s range of processing technologies and proprietary packaging technology, Pyrofree, as examples.
Based in Martillac, D-Lab provides single-use equipment for the production of biological therapies (e.g. immuno-oncology) and “non-conventional processes”, which include products such as sterile powder filling and small batches.
The firm claims it is the first pharmaceutical facility to be specially built for such single use processes, scaling from formulation production to clinical batches down to the microliter scale.
“This acquisition fits perfectly with our strategy of being recognized as a leader in the field of sterile clinical batches manufacturing, matching perfectly the pharmaceutical industry increasing needs”, commented Alain Sainsot, Chairman of Amatsigroup.
Pyrofree
Disposable-Lab’s proprietary Pyrofree technology comprises ready-to-use pyrogen-free packaging vials for aseptic fill and finish of drug candidates.
Pyrogens are endotoxins which can contaminate drug batches and cause fever, with the potential to progress to sepsis and septic shock if they enter the patient’s blood stream.
According to Disposable-Lab the pyrgogen-free vials mean manufacturers do not have to use specialist washing and depyrogenation equipment.
Disposable Lab director Jean Pascal Zambaux, who is also the inventor of the Pyrofree technology, said: “The vials may also be used for commercial safety stocks of injectables,” adding that they are “the most cost-effective solution on the market [for] scalability, from small commercial-size batches.”
CDMO expansion
Originally formed from the amalgamation of 4 pharmaceutical firms, since 2014 Amatsigroup has also acquired Belgian SEPS Pharma, Indiana US-based Amatsigroup Inc., Belgian biomanufacturer, QBiologicals and a French lab nearby in San Augustin, bought from Pierre Fabre.
The firm also previously told Biopharma-Reporter its expansion strategy is focusing on Northern Europe, to include bioclusters across the UK, Switzerland and Germany.
Disposable-Lab reported €2.2 million in revenues last year.
